Autonomix Medical to Present Pain Mitigation Study Data at SIO 2026 Meeting
Autonomix Medical announced that final clinical data evaluating its transvascular radiofrequency ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Society of Interventional Oncology 2026 Annual Scientific Meeting happening February 4-8, 2026 in Savannah, GA. The presentation, titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency Ablation," has been accepted as an ePoster presentation for the conference's Science and Sips Reception, highlighting emerging innovations in interventional oncology. "Pain remains one of the most debilitating and difficult-to-treat complications for patients with pancreatic cancer," said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. "We are pleased to present the final analysis of this study at the SIO 2026 Annual Scientific Meeting, as it highlights the potential of our transvascular RF ablation approach to address a significant unmet clinical need. We believe this minimally invasive therapy may offer a meaningful opportunity to improve pain control and quality of life for patients facing this devastating disease."
